We are thrilled to report that we have received funding from the American Lung Association to study how EGFR-mutant lung cancer cells survive treatment with tyrosine kinase inhibitors (TKI). In this project, we will study how tumor cells persist in the presence of TKI and which vulnerabilities they may possess that can be exploited therapeutically. This will be a collaboration with Aaron Hata, MD, PhD as well as Lecia Sequist, MD, in the MGH Cancer Center.
To move forward with this study we are looking for interested postdoc applicants. Please email your resume and letter as soon as possible. http://www.massgeneral.org/careers/jobsearch.aspx # 3021473